IPF antifibrotic class is evolving with second-generation mechanisms
Idiopathic pulmonary fibrosis treatment has been defined by the two approved antifibrotics (pirfenidone, nintedanib) for a decade. The second-generation pipeline is now reading out, with mechanisms targeting different points in the fibrotic pathway and the potential to combine with the established class.
Reading the signal
Idiopathic pulmonary fibrosis is a progressive interstitial lung disease characterised by chronic fibrosis of pulmonary tissue. The two approved antifibrotics (pirfenidone, nintedanib) slow lung-function decline but do not reverse it, and substantial unmet need remains.
The second-generation pipeline:
- Anti-LPA1 mechanisms: Targeting lysophosphatidic acid receptor-1 signalling, with multiple programs in late-stage development
- Anti-PDE4B mechanisms: Targeting phosphodiesterase 4B with anti-fibrotic and anti-inflammatory effects
- Integrin-targeted programs: Particularly anti-alphavbeta6 integrin programs that target fibroblast activation
- Adjacent inflammatory-pathway programs: Including anti-IL-13 and anti-IL-4Ralpha approaches that address the fibrotic pathway through different points
The combination question is the most active commercial conversation. The first-line standard of care is one of the existing antifibrotics; the second-generation programs are being studied both as monotherapy alternatives and as add-on to the established class.
Commercial implications
For sponsors of second-generation IPF antifibrotics and adjacent fibrotic-disease pipeline:
- The combination-with-existing-class question is decisive. Programs that demonstrate additional benefit on top of existing antifibrotic therapy access a different commercial position than monotherapy alternatives
- Adjacent fibrotic-disease indications (progressive pulmonary fibrosis, cardiac fibrosis, kidney fibrosis, liver fibrosis) are inheriting the commercial frame and the trial-design conventions developed in IPF
- Real-world evidence on lung-function trajectory under different therapeutic regimens is increasingly important for the line-of-therapy positioning conversation
What we are watching
- Late-stage pivotal trial readouts across the second-generation class in the next 12 to 24 months
- Combination protocol data testing add-on efficacy on top of established antifibrotic therapy
- Adjacent fibrotic-disease indications and the rate at which IPF-validated mechanisms move into them
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.